PHARMACOKINETICS OF ORAL GANCICLOVIR IN PEDIATRIC PATIENTS

更昔洛韦是一种人工合成的鸟嘌呤类化合物，可干扰包括巨细胞病毒(CMV)在内的病毒的复制。该药物对各种患者的CMV感染的治疗和慢性抑制治疗都有效。美国食品和药物管理局(FDA)最近批准了一种口服形式的更昔洛韦，作为免疫低下的CMV视网膜炎患者的非肠道药物的替代药物，用于慢性抑制治疗。有几个儿科患者组可能受益于口服更昔洛韦。我们研究的目的是通过测定儿童的吸收曲线和可达到的血药浓度来获得药代动力学数据。

Ganciclovir is a synthetic guanine derivative which interferes with the replication of viruses, including cytomegalovirus (CMV). The drug is effective for both treatment and chronic suppressive therapy of CMV infections in a variety of patients. The Food and Drug Administration has recently approved an oral form of ganciclovir as an alternative to parenteral drug in immunocompromised patient with CMV retinitis for chronic suppressive therapy. There are several pediatric patient groups who may benefit from use of oral ganciclovir. The purpose of our study is to obtain pharmacokinetic data by determining the absorption profile and achievable serum concentrations in children.